GreatPoint Ventures is an early-stage venture capital firm investing between $250k and $20m into Seed, A, and B rounds. The firm was founded in San Francisco, California in 2015.

GreatPoint Ventures

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.  Domainâ€™s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics.  The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies.  The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

Domain Associates

Tao Capital Partners invests in technology, transportation, healthcare, education, and food businesses that have a sustainable positive impact. It is an active investor that supports companies through various stages of their life-cycle. Tao Capital Partners was founded in 2002 and is based in San Francisco, California.

Tao Capital Partners

DNS Capital is an investment office for the business enterprise of Gigi Pritzker, Michael Pucker, and their immediate family that provides long-term control and minority investments in companies. DNS Capital takes a long-term and flexible approach to invest by building relationships with business owners, management teams, and entrepreneurs to align interests, evolve businesses, and create lasting value with a sense of purpose and a sense of humor.

DNS Capital

The 7wire Ventures’ vision is to use the power of mobility, connected devices, the cloud, and sophisticated analytics to further advance industries like healthcare and education. We like to make a difference in things that matter.  The firm was founded on the concept of disrupting the status quo—supporting new ideas, technologies, approaches, and business models for solving society’s most important problems.  7wire Ventures provides funding and operating guidance to companies that challenge the “way things are done.” Through the creation of new businesses, investments in early and growth stage companies, and by complementing funds with insight and experience, we have a track record of transforming great ideas into world-class companies.

7wire Ventures

Wittington Ventures is a venture capital firm investing in the e-commerce/retail, healthcare and food sectors. We invest in companies throughout North America and at all stages of the start-up lifecycle. We are uniquely positioned to help entrepreneurs and their companies through strong affiliations with iconic Canadian brands such as Loblaw, Shoppers Drug Mart, Choice Properties, PC Financial, Joe Fresh and Selfridges Group.

Wittington Ventures

TYH Ventures enables entrepreneurs to turn their own ideas and visions into successful companies. It invests in its companies and gives its partners personal guidance from the very first stages and provided them with all the resources and expert advice they need to turn their visions into disruptive reality. Top 250k Enrichment Emp Range Q12024 - Not Found

TYH Ventures

General Catalyst is a venture capital firm that provides early-stage and growth equity investments. The company provides ongoing momentum that accelerates ideas, careers, and companies toward standout success.

General Catalyst

Synetro is an active seed and early stage investor in web based technology and business services companies. It also operates a private equity business focused on acquiring and turning around software, business services and manufacturing companies.

Synetro Group

Headquartered in Chicago, Illinois, Wasson Enterprise was co-founded in 2016 by Greg Wasson, former CEO of Walgreens, and Kimberly Wasson.

Wasson Enterprise

Pioneer Healthcare Partners, LP (“PHP”) is the private equity arm of Pioneer Group Holdings, LLC (“Pioneer”) the investment office for the Parkinson Family. Pioneer was founded in 2018, by Robert L. Parkinson Jr., the former Chairman and CEO of Baxter International. PHP has a specific focus on investing in industries such as Healthcare, Education, Real Estate and Agriculture.

Pioneer Healthcare Partners

Medical Excellence Capital is an early stage life sciences fund that combines a unique global network of physician scientists with a team of experienced investors, company builders, and operators.

Medical Excellence Capital

Truvian Sciences

Truvian Sciences is a diagnostic company that is transforming the blood testing industry by developing an automated, benchtop system capable of providing lab-accurate results. The company's comprehensive wellness panel covers commonly ordered routine blood tests, including complete blood count, metabolic panel, lipid panel, and more, all from a single sample.

Truvian is a diagnostics company focused on making routine blood testing accessible, convenient, and transparent. The company has developed a fully automated benchtop platform that combines three commonly used testing technologies: Immunoassay, clinical chemistry, and hematology, which will simultaneously perform routine blood testing in minutes from a small blood sample. With an initial testing panel of more than 30 assays, Truvian's platform can run the most commonly ordered tests that account for over 90% of blood test orders.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Truvian Sciences Appoints Top Industry Veterans to its Leadership Team as it Prepares to Commercialize its Automated Benchtop Blood Testing System

Truvian is a diagnostics company focused on making routine blood testing accessible, convenient, and transparent. The company has developed a fully automated benchtop platform that combines three commonly used testing technologies: Immunoassay, clinical chemistry, and hematology, which will simultaneously perform routine blood testing in minutes from a small blood sample. With an initial testing panel of more than 30 assays, Truvian's platform can run the most commonly ordered tests that account for over 90% of blood test orders.Truvian's platform is designed to be a fully automated solution that uses pre-packaged, single-use test kits and requires minimal maintenance. This feature ensures that the technology can be used consistently and reliably in various settings, such as clinics, doctor's offices, and pharmacies, bringing convenient and comprehensive blood testing closer to patients.As of July 2024, the company was undergoing clinical trials for FDA approval.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Truvian Sciences

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless